Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) fell 2.1% during mid-day trading on Monday . The company traded as low as $2.76 and last traded at $2.82, with a volume of 76,205 shares traded. The stock had previously closed at $2.88.

A number of brokerages recently issued reports on AFMD. Leerink Swann began coverage on shares of Affirmed Therapeutics BV in a research note on Saturday, April 2nd. They issued a “buy” rating for the company. Jefferies Group dropped their price target on shares of Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Thursday, May 19th. Wells Fargo & Co. restated a “buy” rating on shares of Affirmed Therapeutics BV in a research note on Wednesday, May 18th. Finally, BMO Capital Markets began coverage on shares of Affirmed Therapeutics BV in a research note on Monday, April 11th. They issued an “outperform” rating and a $7.00 price target for the company. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. Affirmed Therapeutics BV has an average rating of “Buy” and a consensus price target of $9.46.

The firm’s market capitalization is $95.45 million. The company has a 50-day moving average price of $3.15 and a 200-day moving average price of $3.77.

Affirmed Therapeutics BV (NASDAQ:AFMD) last announced its earnings results on Wednesday, May 18th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.08. The firm earned $1.90 million during the quarter, compared to the consensus estimate of $1.88 million. The company’s revenue was down 24.0% on a year-over-year basis. On average, analysts forecast that Affirmed Therapeutics BV will post ($0.95) EPS for the current year.

An institutional investor recently raised its position in Affirmed Therapeutics BV stock. Tekla Capital Management LLC boosted its stake in shares of Affirmed Therapeutics BV (NASDAQ:AFMD) by 29.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 294,213 shares of the biopharmaceutical company’s stock after buying an additional 66,130 shares during the period. Tekla Capital Management LLC owned 0.97% of Affirmed Therapeutics BV worth $2,095,000 as of its most recent SEC filing.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.